Concord Biotech Ltd Q1 FY26 – FY25 Numbers Look Sexy on Paper, but EPS Growth is Playing Hide-and-Seek with FDA Inspectors
1. At a Glance
Concord Biotech, Ahmedabad’s pride and biopharma’s fermentation nerd, has delivered FY25 sales of ₹1,200 crore with a profit of ₹356 crore. A company that once smelt like antibiotics in a college lab now smells like money—though the EPS this quarter looks like it was diluted more than homeopathic medicine. Stock trades at ~50x earnings, because apparently “immunosuppressants” are supposed to suppress rational valuation too.
2. Introduction
Picture this: 1984, while the world was busy with George Orwell’s dystopia, Concord Biotech quietly decided to make its own version—by fermenting APIs in Gujarat. Fast-forward four decades, and this R&D-driven company is now exporting niche APIs to 70+ countries, serving 250+ customers, and pretending like it doesn’t mind FDA inspectors barging into its plants every year like nosy relatives at Diwali.
Investors, meanwhile, are living in two realities:
Reality 1: “Bhai, this is a debt-free, high-margin, R&D-backed pharma gem with 40% OPM and 21% ROE.”
Reality 2: “Arrey baba, stock fell 25% last year, and EPS growth suddenly looks like it went on vacation to Bali.”
Concord plays in niche segments—immunosuppressants, oncology, anti-fungals. These are not your crocin-paracetamol crowd-pleasers. These are high-stakes drugs where margins are fat, but so are the risks.
So the real question—are we looking at India’s fermentation king or just another biotech company fermenting excuses for FDA observations?
3. Business Model – WTF Do They Even Do?
Concord Biotech is basically the biopharma equivalent of that nerdy kid who tinkers with chemistry sets and then ends up owning a billion-dollar lab. They’re not a Cipla churning out generic paracetamols. They focus on niche fermentation-based APIs where only a handful of global players exist.
Segments:
API (75% of revenue): Immunosuppressants, oncology, anti-fungals. Think drugs that keep organ transplant patients alive or help fight cancers—not the cough syrup you buy at the chemist after pani puri.
Formulations (25%): Tablets, capsules, oral suspensions. Recently got ambitious with injectables (new Valthera facility). Formulations grew 42% YoY because apparently tablets are so 2020, injectables are the new flex.
CDMO: Fancy way of saying, “We’ll do R&D for lazy pharma MNCs who’d rather outsource the dirty fermentation work.” Includes strain improvement, process optimization, and downstream processing. Basically, they babysit microbes so they behave.
Backward integration is their jam—they make their own starting materials. No Chinese dependency drama. This makes them cost-efficient, but also ensures their excuse list is shorter when FDA asks tough questions.
In short: Concord is not your average chemist shop supplier. They’re in the high-margin club, but they’ve also invited regulatory headaches to every party.
4. Financials Overview
Quarterly Snapshot (₹ Cr):
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
204
216
430
-5.6%
-52.6%
EBITDA
61
81
189
-24.7%
-67.7%
PAT
44.1
60
140
-26.5%
-68.5%
EPS (₹)
4.21
5.70
13.42
-26.1%
-68.6%
Commentary: Quarterly numbers look like someone accidentally pressed Ctrl+Z on the P&L. Revenue fell, profits collapsed, and EPS shrunk harder than a cheap cotton kurta in the first wash. Annualised EPS at ₹16.8 makes the P/E ~100x if you extrapolate this disaster. Of course, pharma fans will say, “Ignore one bad quarter, look at full year.” To which I say: okay, but don’t also ignore that the stock is already pricing in perfection.
5. Valuation Discussion – Fair Value Range Only
Let’s crunch some numbers:
a) P/E Method:
EPS FY25: ₹34
Industry P/E: 33.6
If Concord traded at industry multiple: ₹34 × 33.6 = ₹1,142
Current multiple (50x) suggests: ₹34 × 50 = ₹1,700
Fair Value Range (all methods blended): 👉 ₹1,100 – ₹1,700 per share
Disclaimer: This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
Concord is in the news more than a Bollywood star in a messy divorce:
USFDA Inspection (May’25): Got 4 procedural observations. Management says “minor issues.” Investors hear “Houston, we have a problem.”
EU GMP Inspection (Aug’25): Passed! Which means Europeans will now happily inject Concord’s drugs while eating croissants.
Acquisition of Stellon Biotech (July’25): 75% stake in a US firm for $1,500 (yes, not typo, $1,500—basically the cost of an iPhone). Okay, fine, it’s actually $1,500 million. Expanding US presence.
New Injectable Facility (Mar’25): Production started. This is their golden goose if FDA doesn’t strangle it first.
ANDA Approvals: Teriflunomide tablets got approved in the US. Fancy name, fancy money.
Green Energy Flex: Invested in Clean Max renewable projects. Because nothing says “We love the planet” like running fermentation plants on solar.
Basically, Concord is juggling FDA obs, EU approvals, US acquisitions, and injectable ambitions—all while pretending quarterly EPS isn’t gasping for breath.
7. Balance Sheet
5-Year Snapshot (₹ Cr):
Year
Assets
Liabilities
Net Worth
Borrowings
2021
1,183
193
990
86
2022
1,313
209
1,094
62
2023
1,514
224
1,280
32
2024
1,701
174
1,516
10
2025
2,034
222
1,802
3
Commentary: Borrowings went from ₹86 Cr to ₹3 Cr—basically debt retired faster than a government babu post 58 years. Net worth
